Axsome Therapeutics Expands Solriamfetol Trial into Adolescent ADHD — Axsome Therapeutics, Inc.

Event summary

Axsome Therapeutics has initiated the FOCUS-3 Phase 3 trial for solriamfetol in adolescents aged 12 to 18 with ADHD.
The trial will enroll approximately 468 patients randomized to receive one of two doses of solriamfetol or placebo for six weeks.
Primary endpoint is change from baseline to week 6 in the ADHD Rating Scale (ADHD-RS-5) total score.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist.

The big picture

Axsome Therapeutics is expanding its pipeline by exploring solriamfetol for adolescent ADHD, a market segment with significant unmet needs. The company aims to leverage solriamfetol's unique mechanism of action to differentiate itself in the competitive ADHD treatment landscape. Success in this trial could open new revenue streams and strengthen Axsome's position in the neuroscience sector.

What we're watching

Trial Execution: The pace at which Axsome Therapeutics enrolls patients in the FOCUS-3 trial will determine its timeline for potential regulatory filings.
Regulatory Pathway: Whether solriamfetol's efficacy and safety data in adolescents will align with previous findings in adults, influencing FDA approval prospects.
Market Opportunity: How Axsome Therapeutics positions solriamfetol against existing ADHD treatments if the trial succeeds, given the disorder's high prevalence and economic burden.